In Vitro Antioxidant Potential, Antidiabetic Activities, and GC–MS Analysis of Lipid Extracts of Chlorella Microalgae

Microalgae represent promising biotechnological platforms for bioactive compound production with pharmaceutical applications. This study investigated the phytochemical composition and biological activities of lipid extracts from three <i>Chlorella</i> species to evaluate their potential as antioxidant and antidiabetic sources. Lipid extraction using chloroform-methanol (2:1) followed by GC-MS analysis revealed distinct compound distributions: 29 compounds in <i>C. ellipsoidea</i>, 33 in <i>C. sorokiniana</i>, and 19 in <i>C. vulgaris</i>. Major bioactive compounds included 2-hexanol, 1,3,6-heptatriene, 4-(2,3-dimethyl-2-cyclopenten-1-yl)-4-methylpentanal, <i>n</i>-hexadecanoic acid, and octadecanoic acid. Biological activity screening encompassed antioxidant assessment through DPPH• and •NO radical scavenging assays and FRAP analysis, while antidiabetic potential was evaluated using α-glucosidase and α-amylase inhibition assays. <i>C. sorokiniana</i> exhibited superior bioactivity with the highest antioxidant capacity (DPPH• IC₅₀ = 329.03 ± 4.30 µg/mL; •NO IC₅₀ = 435.53 ± 10.20 µg/mL; FRAP = 94.74 ± 5.72 mg TE/g) and strongest enzyme inhibition (α-glucosidase IC₅₀ = 752.75 ± 57.95 µg/mL; α-amylase IC₅₀ = 3458.50 ± 104.01 µg/mL). This is the first report on <i>C. sorokiniana</i> strain KU.B2's biological properties and phytochemical profile. These findings establish <i>C. sorokiniana</i> as a valuable biotechnological platform for pharmaceutical bioactive compound development.